Levobupivacaine HCl

Research use only, not for human use.

Levobupivacaine HCl, the pure S(-)-enantiomer of bupivacaine, is a reversible neuronal sodium channel inhibitor, used as a long-acting local anesthetic.

Levobupivacaine HCl, the pure S(-)-enantiomer of bupivacaine, is a reversible neuronal sodium channel inhibitor, used as a long-acting local anesthetic.(In Vitro):Levobupivacaine (0-4 mM; 24 h) does not affect the viability of GES-1 cells but inhibits the viability of HGC27 and SGC7901 cells.Levobupivacaine (2 mM; 24, 48 or 72 h) enhances Erastin-induced inhibitory impact on HGC27 and SGC7901 cell viabilities; induces the levels of Fe2+, iron, and lipid ROS.Levobupivacaine (2 mM; 24 h) enhances the expression of miR-489-3p in HGC27 and SGC7901 cells, increases the levels of Fe2+ and iron.(In Vivo):Levobupivacaine (40 μmol/kg; IP; once daily for 25 days) significantly inhibits SGC7901 cell growth, and enhances the lipid ROS accumulation.Levobupivacaine (5 or 36 mg/kg; IP; single dosage) increases the latency to partial seizures and prevents the occurrence of generalized seizures at low dosage; reduces the latency to N-methyl-d-aspartate (NMDA)-induced seizures and increased seizure severity at high dosage.

Levobupivacaine (0-4 mM; 24 h) does not affect the viability of GES-1 cells but inhibits the viability of HGC27 and SGC7901 cells.Levobupivacaine (2 mM; 24, 48 or 72 h) enhances Erastin-induced inhibitory impact on HGC27 and SGC7901 cell viabilities; induces the levels of Fe2+, iron, and lipid ROS.Levobupivacaine (2 mM; 24 h) enhances the expression of miR-489-3p in HGC27 and SGC7901 cells, increases the levels of Fe2+ and iron. Cell Viability Assay Cell Line:GES-1, HGC27 and SGC790 Concentration:0, 0.5, 1, 2 and 4 mM Incubation Time:24 h Result:Did not affect the viability of normal gastric epithelial GES-1 cell lines but inhibited the viability of HGC27 and SGC7901 cells in a dose-dependent manner.Cell Viability Assay Cell Line:HGC27 and SGC7901 (incubated with 5 μM erastin)Concentration:2 mM Incubation Time:24, 48 or 72 h Result:Enhanced erastin-induced inhibitory impact on HGC27 and SGC7901 cell viabilities; induced the levels of Fe2+, iron, and lipid ROS.RT-PCRCell Line:HGC27 and SGC7901 (incubated with 5 μM erastin) Concentration:2 mM Incubation Time:24 h Result:Enhanced the expression of miR-489-3p in HGC27 and SGC7901 cells, increased the levels of Fe2+ and iron.

Levobupivacaine (40 μmol/kg; IP; once daily for 25 days) significantly inhibits SGC7901 cell growth, and enhances the lipid ROS accumulation.Levobupivacaine (5 or 36 mg/kg; IP; single dosage) increases the latency to partial seizures and prevents the occurrence of generalized seizures at low dosage; reduces the latency to N-methyl-d-aspartate (NMDA)-induced seizures and increased seizure severity at high dosage. Animal Model:CD1 mice (30-35 g; induced epileptic seizures by injecting with NMDA)Dosage:5 or 36 mg/kg Administration:IP; single dosage Result:Increased the latency to partial seizures and prevented the occurrence of generalized seizures at 5 mg/kg; reduced the latency to NMDA-induced seizures and increased seizure severity at 36 mg/kg.Animal Model:SCID nude mice (6-8 weeks; subcutaneously injected with 5×106 SGC7901 cells)Dosage:40 μmol/kg Administration:IP; once daily for 25 days Result:Significantly inhibited SGC7901 cell growth, and enhanced the lipid ROS accumulation.

——

Membrane Transporter/Ion Channel

Sodium Channel

Sodium Channel

Other Indications

——

27262-48-2

324.89

C18H28N2O·HCl

>98% (HPLC)

DMSO:64 mg/mL (196.98 mM); Ethanol:57 mg/mL (175.44 mM); Water:64 mg/mL (196.98 mM)

CCCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C.Cl

——

(-20℃)

With Ice Pack

≥ 2 years